VSTM — Presentation of VS-7375 Data at ASCO Annual Meeting
Jun 2, 2025, 5:00:00 AM UTC
Summary
Verastem Oncology will present updated data from the Phase 1/2 study of VS-7375, an oral KRAS G12D inhibitor developed in partnership with GenFleet Therapeutics, at the 2025 ASCO Annual Meeting on June 2, 2025, in Chicago, IL. The study focuses on treating patients with RAS/MAPK pathway-driven cancers. The event will be part of an R&D investor webcast where Verastem will also discuss encouraging results from its RAMP 205 trial, showing a response rate of 83% in frontline metastatic pancreatic ductal adenocarcinoma with its treatment combination. Investors will watch for more mature data on VS-7375, as its clinical development could provide significant avenues for market expansion beyond previously approved indications.
Company
VERASTEM INC (VSTM)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.verastem.comSimilar Events
Oral Presentation at the 2025 ASCO Annual Meeting
Candel Therapeutics, Inc. will present data from its phase 3 clinical trial of CAN-2409 at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, IL, scheduled for May 30 to June 3, 2025. The study focuses on patients with intermediate-to-high risk localized prostate cancer and aims to provide insights into the efficacy and safety of CAN-2409. This oral presentation highlights Candel's ongoing developments in cancer treatment, particularly in the prostate cancer domain, which may impact investor perceptions regarding the company's future market position and product pipeline.
Oral presentationPresentation of Phase 3 Clinical Trial Results at ASCO 2025
Candel Therapeutics, Inc. announced that phase 3 clinical trial results for its prostate cancer drug, aglatimagene besadenovec (CAN-2409), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 to June 3, 2025, in Chicago, IL. The trial, involving 745 patients, demonstrated a statistically significant improvement in disease-free survival (p=0.0155) and a 30% reduction in the risk of cancer recurrence or death in those treated with CAN-2409 compared to placebo. This follows initial results released in December 2024, marking a potential significant advancement in treatment for intermediate-to-high-risk localized prostate cancer patients.
Drug PresentationConclusion of ASCO Annual Meeting
The American Society of Clinical Oncology (ASCO) Annual Meeting concluded on June 3, 2025, in Chicago, Illinois, where interim results for Perspective Therapeutics, Inc.'s Phase 1/2a clinical trial of [212Pb]VMT-α-NET were presented. This investigational drug targets unresectable or metastatic somatostatin receptor subtype 2-expressing neuroendocrine tumors (NETs), with implications for improved treatment and diagnosis in this patient population.
American Society of Clinical Oncology Annual MeetingPresentation of Rinatabart sesutecan Data at ASCO
Genmab A/S will present new data on rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1-inhibitor antibody-drug conjugate, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. This includes the first results from a Phase 1/2 trial in patients with recurrent or advanced endometrial cancer. The presentation is part of Genmab's broader commitment to advancing treatment options for cancers with limited therapies, emphasizing the potential of rinatabart sesutecan in addressing rising mortality rates in endometrial cancer. The event is scheduled for June 1, 2025, at 16:00 CEST.
presentation